Erlotinib treatment of meningeal carcinomatosis in lung cancer: more is better

Ann Oncol. 2014 Oct;25(10):2093-2094. doi: 10.1093/annonc/mdu261. Epub 2014 Jul 23.

Authors

A Cessot¹, B Blanchet², F Goldwasser³

Affiliations

¹ Department of Medical Oncology, Université Paris Descartes. Electronic address: anatole.cessot@cch.aphp.fr.
² Department of Pharmacology, Cochin Teaching Hospital, Paris, France.
³ Department of Medical Oncology, Université Paris Descartes.

PMID: 25057169
DOI: 10.1093/annonc/mdu261

No abstract available

Publication types

Case Reports
Letter

MeSH terms

ErbB Receptors / genetics
Erlotinib Hydrochloride
Female
Humans
Lung Neoplasms / drug therapy
Lung Neoplasms / genetics
Lung Neoplasms / pathology*
Meningeal Carcinomatosis / drug therapy
Meningeal Carcinomatosis / genetics
Meningeal Carcinomatosis / pathology*
Meningeal Carcinomatosis / secondary
Middle Aged
Neoplasm Metastasis
Quinazolines / administration & dosage*
Quinazolines / adverse effects

Substances

Quinazolines
Erlotinib Hydrochloride
EGFR protein, human
ErbB Receptors